TY - JOUR
T1 - Robust suppression of cardiac energy catabolism with marked accumulation of energy substrates during lipopolysaccharide-induced cardiac dysfunction in mice
AU - Umbarawan, Yogi
AU - Syamsunarno, Mas Rizky A.A.
AU - Obinata, Hideru
AU - Yamaguchi, Aiko
AU - Sunaga, Hiroaki
AU - Matsui, Hiroki
AU - Hishiki, Takako
AU - Matsuura, Tomomi
AU - Koitabashi, Norimichi
AU - Obokata, Masaru
AU - Hanaoka, Hirofumi
AU - Haque, Anwarul
AU - Kunimoto, Fumio
AU - Tsushima, Yoshito
AU - Suematsu, Makoto
AU - Kurabayashi, Masahiko
AU - Iso, Tatsuya
N1 - Funding Information:
This work was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (nos. 24390194 and 16H05294 to MK and no. 26461123 to TI), a grant from the Japan Cardiovascular Foundation, a grant from Gunma University Initiative for Advanced Research (no. 140908272400 to MK), a grant from Japan Agency for Medical Research and Development (no. 10030-14120 to MK) and a grant from MSD Life Science Foundation (no. 141602441000 to TI). CE/MS-based metabolome analysis was supported by Biobank Japan Project by AMED. M.S. was the leader of the ERATO Project until March 2015.
Publisher Copyright:
© 2017 The Author(s)
PY - 2017/12
Y1 - 2017/12
N2 - Background Myocardial contractile dysfunction in sepsis has been attributed mainly to increased inflammatory cytokines, insulin resistance, and impaired oxidative phosphorylation of fatty acids (FAs). However, precise molecular mechanisms underlying the cardiac dysfunction in sepsis remain to be determined. We previously reported major shift in myocardial energy substrates from FAs to glucose, and increased hepatic ketogenesis in mice lacking fatty acid-binding protein 4 (FABP4) and FABP5 (DKO). Purpose We sought to determine whether a shift of energy substrates from FAs to glucose and increased availability of ketone bodies are beneficial or detrimental to cardiac function under the septic condition. Methods Lipopolysaccharide (LPS, 10 mg/kg) was intraperitoneally injected into wild-type (WT) and DKO mice. Twelve hours after injection, cardiac function was assessed by echocardiography and serum and hearts were collected for further analyses. Results Cardiac contractile function was more deteriorated by LPS injection in DKO mice than WT mice despite comparable changes in pro-inflammatory cytokine production. LPS injection reduced myocardial uptake of FA tracer by 30% in both types of mice, while uptake of the glucose tracer did not significantly change in either group of mice in sepsis. Storage of glycogen and triacylglycerol in hearts was remarkably increased by LPS injection in both mice. Metabolome analysis revealed that LPS-induced suppression of pool size in the TCA cycle was more enhanced in DKO hearts. A tracing study with 13C6-glucose further revealed that LPS injection substantially reduced glucose-derived metabolites in the TCA cycle and related amino acids in DKO hearts. Consistent with these findings, glucose oxidation in vitro was similarly and markedly reduced in both mice. Serum concentration of β-hydroxybutyrate and cardiac expression of genes associated with ketolysis were reduced in septic mice. Conclusions Our study demonstrated that LPS-induced cardiac contractile dysfunction is associated with the robust suppression of catabolism of energy substrates including FAs, glucose and ketone bodies and accumulation of glycogen and triacylglycerol in the heart. Thus, a fuel shift from FAs to glucose and/or ketone bodies may be detrimental rather than protective under septic conditions.
AB - Background Myocardial contractile dysfunction in sepsis has been attributed mainly to increased inflammatory cytokines, insulin resistance, and impaired oxidative phosphorylation of fatty acids (FAs). However, precise molecular mechanisms underlying the cardiac dysfunction in sepsis remain to be determined. We previously reported major shift in myocardial energy substrates from FAs to glucose, and increased hepatic ketogenesis in mice lacking fatty acid-binding protein 4 (FABP4) and FABP5 (DKO). Purpose We sought to determine whether a shift of energy substrates from FAs to glucose and increased availability of ketone bodies are beneficial or detrimental to cardiac function under the septic condition. Methods Lipopolysaccharide (LPS, 10 mg/kg) was intraperitoneally injected into wild-type (WT) and DKO mice. Twelve hours after injection, cardiac function was assessed by echocardiography and serum and hearts were collected for further analyses. Results Cardiac contractile function was more deteriorated by LPS injection in DKO mice than WT mice despite comparable changes in pro-inflammatory cytokine production. LPS injection reduced myocardial uptake of FA tracer by 30% in both types of mice, while uptake of the glucose tracer did not significantly change in either group of mice in sepsis. Storage of glycogen and triacylglycerol in hearts was remarkably increased by LPS injection in both mice. Metabolome analysis revealed that LPS-induced suppression of pool size in the TCA cycle was more enhanced in DKO hearts. A tracing study with 13C6-glucose further revealed that LPS injection substantially reduced glucose-derived metabolites in the TCA cycle and related amino acids in DKO hearts. Consistent with these findings, glucose oxidation in vitro was similarly and markedly reduced in both mice. Serum concentration of β-hydroxybutyrate and cardiac expression of genes associated with ketolysis were reduced in septic mice. Conclusions Our study demonstrated that LPS-induced cardiac contractile dysfunction is associated with the robust suppression of catabolism of energy substrates including FAs, glucose and ketone bodies and accumulation of glycogen and triacylglycerol in the heart. Thus, a fuel shift from FAs to glucose and/or ketone bodies may be detrimental rather than protective under septic conditions.
KW - Cardiac function
KW - Energy metabolism
KW - Fatty acid
KW - Glucose
KW - Sepsis
UR - http://www.scopus.com/inward/record.url?scp=85031754132&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031754132&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2017.09.003
DO - 10.1016/j.metabol.2017.09.003
M3 - Article
C2 - 28941596
AN - SCOPUS:85031754132
SN - 0026-0495
VL - 77
SP - 47
EP - 57
JO - Metabolism: clinical and experimental
JF - Metabolism: clinical and experimental
ER -